Why Isn’t Big Pharma Investing in GLP-1 Trials for Substance Use Disorders?
There’s a noticeable lack of pharmaceutical company trials of GLP-1 drugs as treatments for substance use disorders.
Does Ozempic Cause Weight Loss by Impacting the Brain or the Gut?
A study from The Netherlands examines the impacts of GLP-1 agonists on the central nervous system using fMRI.
Is Ozempic the Gateway Drug for CBT?
Two recent studies show nearly twice the weight loss for patients who undergo group CBT in addition to taking liraglutide, a GLP-1 agonist.
A Pathway Out of Addiction?
Could a wearable ultrasound device be a pathway out of addiction, or even a way to prevent it?
Testing Advances on Psychedelic Therapies for Substance Use Disorders
Positive results have caused a surge in clinical trials of psychedelic substances to treat substance use disorders.
San Jose Launches First-In-The-Country Addiction Treatment Program for Teens
The Santa Clara County Valley Medical Center is setting the gold standard in comprehensive care for teens suffering from substance use disorders.